KDR and cancer: Among known key RCC and cancer genes, we identify KDR/VEGFR-263,64 (minimum p-value = 4.8×10−10), target for anti-angiogenic therapies for RCC, to be trans-associated to RCC-loci at binding sites of 48 unique TFs, as well as AXL65 (minimum p-value = 2.9×10−8) and FBP166 (minimum p-value = 3.9×10−11), associated to 8 and 6 unique TFs respectively.